Formulation Technologies for the Development of Dry Powders for Inhalation

Register free: https://www.pharmtech.com/pt/dry-powders

Event Overview:
Pulmonary and nasal delivery are the preferred routes of administration for the majority of locally acting drugs exerting their effects on the airways or nasal mucosa. For both routes of administration, molecules are most often highly potent small molecules. Pulmonary products are primarily delivered via metered dose inhalers, Dry Powder Inhalers (DPIs) with carrier-based formulations, or nebulized solutions; nasal products are delivered as liquid solutions or suspensions. Drug pipelines have now expanded to include inhaled high-dose products, biotherapeutics (peptides, proteins, gene therapies, and phages), and systemically acting therapeutics, which serve as alternatives to intravenous and sub-cutaneous injected dosage forms. New technologies, such as spray drying, are gaining traction to address the complexity of delivering these molecules through the pulmonary or nasal routes. This webinar will discuss challenges and key considerations for spray-dried formulations for inhalation, along with a review of current technologies and approved products utilizing particle engineering approaches.

Key Learning Objectives:

• Spray drying as an approach for the development of carrier-free systems
• Challenges and key considerations for spray-dried formulations for inhalation
• Review of current technologies and approved products utilizing particle engineering approaches

Who Should Attend:

Biopharma, Pharma, and consultants working in the oral inhalation space

Speakers

Alan Watts
Director Innovation and Partnerships - Orally Inhaled Delivery
Catalent

Alan Watts, Ph.D., has focused his career on developing drugs for respiratory delivery, leveraging nearly 15 years of experience developing inhalation products in industrial and academic settings. Watts joined Catalent from Savara Pharmaceuticals, where he spent four years working in pharmaceutical development on two late-stage inhalation programs. Prior to that, Watts was a Research Assistant Professor at the University of Texas at Austin, where he created and oversaw an aerosol testing lab, taught courses on pharmaceutical entrepreneurship and pharmacokinetics, and co-invented a novel dry powder inhalation platform.

Watts has served in multiple roles within the American Association of Pharmaceutical Scientists (AAPS), as a reviewer for several pharmaceutical journals, and as proceedings editor for the Respiratory Drug Delivery (RDD) conference.

Watts holds a doctorate in Pharmaceutics from the University of Texas at Austin.

Qi (Tony) Zhou, Ph.D.
University Faulty Scholar Associate Professor, Department of Industrial and Physical Pharmacy, College of Pharmacy
Purdue University, Indiana

Tony Zhou, Ph.D., is a recognized expert in inhalation dosage forms and pulmonary drug delivery systems. He is an editor of AAPS PharmSciTech and an Editorial Board Member of nine pharmaceutical journals, including International Journal of Pharmaceutics, Pharmaceutical Research, and Journal of Pharmaceutical Sciences. He has published over 100 journal articles and filed eight patents/applications. Zhou’s research has attracted more than $8 million in funding, including NIH R01 grants and many industrial projects. His significant contribution to the field of pharmaceutical science has been recognized with many prestigious awards, including the 2021 AAPS Emerging Leader Award, the 2019 DDL Emerging Scientist Award from The Aerosol Society, the 2018 Rising Star Scholarship Award from the National Institute for Pharmaceutical Technology & Education (NIPTE), the 2017 New Investigator Award from International Society of Aerosols in Medicines (ISAM), and the 2016 Emerging Researcher Award from International Pharmaceutical Excipients Council of the Americas Foundation (IPEC).
Zhou holds a doctorate in pharmaceutics from Monash University, Victoria, Australia.

Register free: https://www.pharmtech.com/pt/dry-powders